A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-Like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to less than 24 Month-Old Children and in 2 Month-Old Infants.

Trial Profile

A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-Like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to less than 24 Month-Old Children and in 2 Month-Old Infants.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs MEDI 534 (Primary)
  • Indications Parainfluenza virus infections; Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Sep 2011 Planned end date changed from 1 Jan 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 02 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top